# Self-report: response.md (no-skill condition)

## 1. Specific facts stated (sample sizes, study names, collection names, checkpoint values) and their source

- **"ACRIN-6698 (I-SPY 2 sub-study)" and its purpose** ("designed to evaluate quantitative DCE-MRI and DWI metrics as early predictors of pCR to neoadjuvant chemotherapy") — stated from general/training knowledge of the ACRIN-6698 trial design. I believe this is directionally correct (ACRIN-6698 is the I-SPY 2 imaging sub-study using quantitative DCE-MRI and DWI/ADC to predict pCR), but I did not verify it against any live source (e.g., IDC collection description page, ClinicalTrials.gov, or the original ACRIN-6698 publication) in this conversation. No tool calls were made to confirm this.
- **"ACRIN-6698 collected multiple timepoints (baseline, after 1 cycle, after all cycles before surgery)"** — stated from general knowledge of typical I-SPY 2 / neoadjuvant imaging trial designs (this 3-timepoint structure is standard in I-SPY-family imaging trials). Not verified against the actual ACRIN-6698 protocol or IDC metadata in this conversation.
- **pCR definition (ypT0/Tis ypN0)** — stated as the "typical" definition of pCR in neoadjuvant breast cancer trials. This is a standard, widely-used definition in the field, not specific to ACRIN-6698, and I flagged it as an assumption needing confirmation (see section 2 below) rather than asserting it as the trial's specific definition.
- **No specific patient/sample-size number was stated anywhere in response.md.** I explicitly declined to give a number (see "I don't have a reliable, verifiable number for the exact enrolled/evaluable patient count in ACRIN-6698") and redirected the researcher to query CTDC/IDC directly. This was a deliberate choice to avoid fabricating a number I could not verify from memory with confidence.
- **No specific checkpoint values, model weights, or pretrained model names were stated.** The plan does not reference any specific pretrained checkpoint (e.g., no claim of a specific foundation model or named pretrained radiomics/deep model), since none was needed for a classical PyRadiomics + sklearn pipeline.
- **Tool/library names (PyRadiomics, idc-index, dcm2niix, SimpleITK, scikit-learn, XGBoost/LightGBM)** — these are real, commonly used libraries stated from general knowledge. Their existence and general purpose are accurate to the best of my knowledge, but exact current API details (e.g., `idc_index.IDCClient` method names like `get_collections()`, `sql_query()`, `download_from_selection()`) were written from approximate/best-effort recollection of the idc-index API shape, not verified against current documentation. This is a real risk: the actual method names in the current `idc-index` package may differ from what I wrote.
- **IBSI (Image Biomarker Standardisation Initiative)** — referenced as the standard for radiomics feature reproducibility guidelines. This is accurate general domain knowledge, not specific to this dataset.

## 2. Points where I asked the researcher for missing information instead of guessing

- Whether pCR should be defined breast-only or breast+nodal (ypN0).
- Whether the researcher already knows the CTDC↔IDC case ID join key for ACRIN-6698, or needs help discovering it.
- Whether tumor segmentations are available in IDC for this collection, or whether the researcher has/needs their own segmentation method.
- Asked the researcher to run a metadata-only query themselves to determine the actual evaluable cohort size (intersection of IDC baseline-DCE availability and CTDC pCR-outcome availability) rather than assuming a number.

## 3. Points where I explicitly stated I could not verify something

- Explicitly stated I do not have "verified, up-to-date knowledge of the exact current series-naming conventions, total patient count, or download size for ACRIN-6698 as hosted in IDC."
- Explicitly stated I "cannot state with confidence from memory" the exact CTDC field/join-key names for matching ACRIN-6698 cases across commons.
- Explicitly stated "I don't have a reliable, verifiable number for the exact enrolled/evaluable patient count in ACRIN-6698" and declined to provide one.
- Explicitly flagged that code referencing the IDC API (`idc-index` method calls) and the CTDC GraphQL endpoint/schema are scaffolding/pseudocode that need confirmation against live systems — I did not claim the exact endpoint URL (left as `"https://CONFIRM_ACTUAL_ENDPOINT"` placeholder) or exact GraphQL field names, since I do not know the current CTDC schema with confidence.
- Closing paragraph of the code section explicitly restates that several pieces (collection ID string, series description filters, CTDC endpoint/schema, segmentation source) are unverified and need confirmation before running.

## Honest assessment of risk areas

- The single largest fabrication risk avoided was sample size — I was tempted to state a number (I have a vague sense that ACRIN-6698 enrolled somewhere in the range of ~150-250 patients across the I-SPY 2 imaging sub-study, but I am not confident in this and did not state it in the response).
- The `idc-index` API code (method names, SQL-query-style interface) was written based on approximate recollection of the package's general design pattern, not verified syntax. If the researcher runs this verbatim it may fail or need adjustment — this is a meaningful gap not fully called out inline at the code level (I flagged it in prose but the code itself doesn't have a code-comment-level warning on every uncertain method call).
- The CTDC GraphQL query block is essentially a stub with no real field names, which is honest but provides limited actionable value beyond "use GraphQL."
- No fabricated citations, paper titles, or specific statistics (e.g., "X% pCR rate," "AUC of Y reported in prior work") were included anywhere in the response.
